SLC5A2 and hydrops fetalis: The use of sodium-glucose cotransporter 2 (SGLT2) inhibitors was higher in diabetic patients (62.8% vs. 40.2%; p < 0.05), but no significant differences were observed regarding other guideline-recommended HF drugs.